Results of a new study demonstrate that computer models can predict how HIV patients whose drug therapy is failing will respond to a new treatment. Crucially for patients in poorer countries, the models do not require the results of expensive drug resistance tests to make their predictions. The study also showed that the models were able to identify alternative drug combinations that were predicted to work in cases where the treatment used in the clinic had failed, suggesting that their use could avoid treatment failure.
14 March 2013 | Eurekalert Inf Dis
Patients who switched from suppressive triple-drug therapy to boosted protease-inhibitor monotherapy had unreasonably high rates of treatment failure.
05 December 2012 | Journal Watch
HIV resistant to the integrase inhibitor raltegravir and isolated from patients taking a failing raltegravir regimen remained largely susceptible to the integrase inhibitor dolutegravir in phenotypic susceptibility testing. Raltegravir-resistant virus carrying a mutation at position Q148 had more reduced susceptibility to dolutegravir than isolates with other raltegravir mutations.
13 November 2012 | International AIDS Society
Adding pegylated interferon alfa to antiretroviral therapy (ART) for HIV may help some people control viral replication when they interrupt treatment, according to a small study reported at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012) and published in the October 26, 2012, advance online edition of the Journal of Infectious Diseases.
12 November 2012 | HIVandHepatitis.com
Researchers in Sweden and Switzerland have been conducting clinical trials of PI monotherapy and HIV-related neurological research. Recently, two teams have separately reported that their data strongly suggest that injury to cells within the brain has occurred in some participants when exposed to PI monotherapy. The Swedish team recommends that PI monotherapy be used cautiously until further clinical trials are completed and more detailed information on the brain health of participants becomes available.
02 November 2012 | CATIE
In a randomized trial, switching away from the booster drug allowed treatment-experienced patients to keep HIV under control and reduced toxicity, according to David Wohl, MD, of the University of North Carolina in Chapel Hill.
13 September 2012 | MedPage Today
Janssen Therapeutics, Division of Janssen Products, LP, announced that the U.S.
Food and Drug Administration (FDA) has approved INTELENCE® (etravirine) to be
administered in combination with other antiretroviral (ARV) medications for
treatment of human immunodeficiency virus 1 (HIV-1) in treatment-experienced
pediatric patients (6 years to less than 18 years old) who are experiencing
virologic failure with HIV-1 strains resistant to a non-nucleoside reverse
transcriptase inhibitor (NNRTI) and other ARVs.
28 March 2012 | Janssen press release
Under a new pact Gilead will combine its new boosting agent cobicistat with J&J's Prezista, a protease inhibitor. The companies also outlined ongoing talks on a separate pact on the
development and commercialization of a future single-tablet regimen
combining Prezista with Gilead's Emtriva, its experimental GS 7340 and
cobicistat. Gilead would be responsible for the development and
commercialization of the new STR on a worldwide basis.
28 June 2011 | FierceBiotech
AS part of efforts to expand treatment for People Living With HIV/AIDS (PLWHAs) and beat drug-resistance, an Indian company, Emcure Pharmaceuticals, has donated second line Anti Retroviral (ARV) drugs to the National Agency for the Control of AIDS
19 May 2011 | Moreover.com HIV/AIDS feed
The largest clinical trial to investigate treatment options for individuals whose first combination of anti-HIV medicines is no longer working has been announced following the recruitment of 1,200 HIV-positive individuals from across five African
18 May 2011 | University College Dublin